Active surveillance is a structured prostate-cancer management strategy that delays immediate surgery or radiation while closely monitoring for evidence that the cancer has become more clinically significant. It is used primarily for suitable low-risk localized prostate cancer and for carefully selected favorable intermediate-risk disease. Surveillance works only when the initial cancer has been characterized accurately and follow-up is maintained with PSA testing, clinical review, MRI when appropriate and repeat biopsy according to the surveillance protocol.
A patient is generally considered for active surveillance when prostate cancer appears biologically favorable, remains localized and can be monitored safely without losing a realistic opportunity for curative treatment later. PSA or MRI change does not automatically mean treatment is required. Those changes usually trigger reassessment. Histological progression on repeat biopsy—such as clinically important upgrading, adverse architecture or increasing disease extent—is a stronger reason to discuss surgery or radiation.
01What Is Active Surveillance for Prostate Cancer?
Active surveillance is delayed treatment with a safety system
Active surveillance is used when the immediate risks and side effects of prostate-cancer treatment may outweigh the near-term risk posed by the cancer.
The strategy has two linked goals:
- avoid or delay unnecessary treatment for cancers that may never cause symptoms or shorten life;
- identify clinically meaningful progression early enough that curative treatment can still be offered when needed.
The broader treatment framework is explained in Prostate Cancer Treatment.
Is active surveillance the same as doing nothing?
No.
A true active-surveillance program has a defined follow-up plan.
That plan commonly includes:
- serial PSA measurements;
- clinical review and selected digital rectal examination;
- prostate MRI when appropriate;
- repeat prostate biopsy according to the protocol;
- and reassessment of Grade Group, tumor extent and other risk features.
The surveillance strategy is therefore active: the patient is not being treated immediately, but the cancer is being repeatedly reassessed.
Why can treatment be safely delayed in selected patients?
Many screen-detected Grade Group 1 prostate cancers have a slow natural history.
Immediate prostatectomy or radiation can produce urinary, sexual or bowel adverse effects years before the cancer would otherwise have caused harm.
Active surveillance shifts the timing of treatment so that treatment is used when the balance between cancer risk and treatment burden becomes more favorable.
Does active surveillance mean treatment will never be needed?
No.
Some men remain untreated for many years. Others are reclassified and move to surgery or radiation.
The transition to treatment is not a failure of surveillance. Detecting biologically important change before the window for cure closes is one of the purposes of surveillance.
Active surveillance is not a promise that treatment can be avoided permanently. It is a strategy for avoiding treatment that is not yet justified while maintaining structured opportunities to detect progression and intervene if the cancer becomes more clinically significant.
02Who Is Eligible for Active Surveillance?
Low-risk localized prostate cancer is the core surveillance population
Current European guidance recommends active surveillance as standard care for suitable patients with low-risk disease and allows surveillance in selected favorable intermediate-risk cases.
Eligibility is not decided from one number.
The initial assessment can include:
- clinical stage;
- Grade Group and Gleason pattern;
- PSA;
- PSA density;
- number and extent of positive biopsy cores;
- MRI findings;
- presence or absence of adverse histological architecture;
- age, comorbidity and life expectancy;
- and willingness to complete repeat testing.
What does low-risk disease usually mean?
Risk systems vary, but low-risk localized disease generally combines:
- Grade Group 1 disease;
- a relatively low PSA profile;
- and cancer that appears confined to the prostate without higher-risk clinical features.
Stage and Grade Group should be interpreted together. Review Prostate Cancer Stages and Gleason Score vs Grade Group for those components.
Can Grade Group 2 prostate cancer be monitored?
Sometimes.
Selected favorable intermediate-risk cancers can be considered for surveillance when the pattern-4 component and overall disease volume are limited.
As one concrete guideline example, the European Association of Urology describes selected Grade Group 2 candidates using features such as:
- less than 10% Gleason pattern 4;
- PSA below 10 ng/mL;
- clinical stage no higher than cT2a;
- low disease extent on imaging;
- and low biopsy tumor volume, such as no more than three positive Grade Group 2 cores with no more than 50% cancer involvement per core.
Those are guideline-specific examples rather than universal eligibility rules. Programs can use somewhat different thresholds.
Why is Grade Group 2 selection stricter?
Because Grade Group 2 contains Gleason pattern 4, which increases the risk of progression compared with Grade Group 1 disease.
The amount and type of pattern 4 therefore matter.
Who should generally not enter an active-surveillance program?
Surveillance is generally inappropriate when the cancer already has features suggesting that delaying definitive treatment could create an unacceptable risk.
Examples include:
- unfavorable intermediate-risk disease;
- Grade Group 3 or higher disease in standard surveillance frameworks;
- high-risk localized prostate cancer;
- clinically significant local extension;
- regional-node or distant metastatic disease;
- and adverse pathology such as cribriform or intraductal carcinoma in guideline frameworks that specifically exclude these findings.
Why do cribriform and intraductal carcinoma matter?
These growth patterns are associated with more aggressive behavior.
Current EAU recommendations specifically exclude biopsy-proven cribriform or intraductal histology from active surveillance.
Does age determine eligibility?
Not by itself.
A healthy 70-year-old and a frail 70-year-old can have very different expected benefits from surveillance, definitive treatment or watchful waiting.
Life expectancy and comorbidity are therefore more clinically useful than chronological age alone.
Intermediate-risk disease should not be treated as one surveillance category. Selected low-volume Grade Group 2 cancers may be monitored, but unselected intermediate-risk disease carries greater long-term progression risk. Grade Group 3 disease is excluded from standard EAU active-surveillance protocols.
03How Is Prostate Cancer Monitored During Active Surveillance?
Surveillance combines different tests because each test answers a different question
No single test can reliably monitor every dimension of prostate cancer.
| Surveillance tool | Main question | What a change can mean | Important limitation |
|---|---|---|---|
| PSA | Is prostate-associated biomarker activity changing? | May suggest greater cancer activity or another prostate process. | PSA is not cancer-specific and can fluctuate. |
| PSA density | How high is PSA relative to prostate volume? | Can refine concern when PSA rises. | Depends on accurate prostate-volume measurement. |
| DRE | Has palpable local disease changed? | A new or larger abnormality can trigger reassessment. | Limited sensitivity; MRI has reduced reliance on DRE in some protocols. |
| MRI | Has a known lesion changed or has a new suspicious lesion appeared? | Can prompt targeted re-biopsy. | MRI progression alone should not automatically equal treatment. |
| Repeat biopsy | Has grade, architecture or tissue-level tumor burden changed? | Can confirm pathological reclassification. | Sampling error and procedure burden remain important. |
How often is PSA checked?
Protocols differ.
Current EAU guidance uses PSA at least every six months as part of a strict surveillance strategy.
A shorter interval may be used when a new PSA result needs confirmation or when another feature raises concern.
Why should an unexpected PSA rise often be repeated?
PSA can rise for reasons unrelated to cancer progression.
Transient causes can include:
- prostate inflammation;
- urinary retention;
- recent instrumentation;
- ejaculation;
- and other benign prostate changes.
A sudden isolated PSA increase therefore should be interpreted in context rather than treated as proof that surveillance has failed.
What is PSA doubling time?
PSA doubling time estimates how quickly PSA is increasing.
A shorter doubling time can increase concern for biological progression.
Current EAU guidance recommends MRI and repeat biopsy when PSA is rising with a PSA doubling time under three years.
How is MRI used during surveillance?
Multiparametric MRI helps assess:
- known lesion size;
- appearance of new lesions;
- changes in lesion conspicuity;
- possible local extension;
- and where repeat targeted biopsy should be directed.
MRI is particularly useful when the original diagnostic pathway did not include high-quality pre-biopsy MRI and targeted sampling.
Can a stable MRI replace repeat biopsy?
Usually not by itself.
EAU guidance states that stable MRI does not automatically make repeat biopsy unnecessary. However, biopsy frequency can be individualized in carefully selected low-risk patients with stable MRI and low, stable PSA density.
Why is repeat biopsy still important?
Because histological change is one of the strongest indicators that the cancer has been reclassified.
Repeat biopsy can identify:
- higher Grade Group;
- greater pattern-4 burden;
- increasing tumor volume;
- cribriform or intraductal architecture;
- or significant cancer that was under-sampled initially.
How often is repeat biopsy performed?
There is no universal schedule.
Current EAU recommendations describe repeated biopsy with or without MRI every two to three years within a strict protocol, while the accompanying evidence discussion notes that a 1-, 4- and 7-year biopsy schedule has also commonly been used.
Actual timing can be modified by:
- baseline MRI and biopsy quality;
- PSA density;
- previous negative repeat biopsy;
- age and life expectancy;
- MRI stability;
- and changes in other risk features.
MRI is a decision-support tool, not an automatic treatment trigger. MRI progression should lead to repeat tissue assessment when clinically appropriate. Current EAU guidance specifically recommends confirming histological progression before changing treatment strategy.
04What Triggers Treatment During Active Surveillance?
Signals for reassessment are different from triggers for treatment
One of the most important surveillance distinctions is:
a test can trigger investigation without triggering treatment.
Examples:
- a PSA rise can trigger repeat PSA testing;
- a short PSA doubling time can trigger MRI and biopsy;
- MRI progression can trigger targeted repeat biopsy;
- a new palpable abnormality can trigger restaging;
- but treatment is generally based on the confirmed change in the cancer rather than on the signal alone.
Is a rising PSA enough to stop active surveillance?
Usually not by itself.
PSA is useful because it is inexpensive and repeatable, but it is not specific to cancer.
An isolated rise should usually be confirmed and interpreted alongside PSA density, doubling time, prostate size, MRI and pathology.
Does MRI progression automatically mean surgery or radiation?
No.
MRI can identify a lesion that has enlarged or become more suspicious, but imaging progression does not always equal histological progression.
Current EAU guidance recommends repeat biopsy to confirm histological progression before changing treatment on the basis of MRI progression.
What biopsy findings are strong reasons to discuss treatment?
Important pathological reasons for reclassification can include:
- upgrade to a clearly less favorable Grade Group;
- greater amount of Gleason pattern 4;
- increasing cancer volume on repeat biopsy;
- newly identified cribriform architecture;
- newly identified intraductal carcinoma;
- or other pathological findings that move the cancer outside the program’s eligibility criteria.
EAU guidance identifies reclassification to Grade Group 3 or higher or detection of cribriform/intraductal growth as major histopathological reasons to change management.
What if Grade Group 2 disease remains low volume?
Some selected men can remain on surveillance.
For Grade Group 2 patients enrolled under favorable-intermediate criteria, the question is whether repeat biopsy still shows low-volume, favorable disease.
In the EAU example framework, increasing beyond three positive Grade Group 2 cores or more than 50% cancer involvement in a core on systematic repeat biopsy is a reason for reclassification.
Can a patient choose treatment even without pathological progression?
Yes.
A surveillance strategy depends on informed preference.
Persistent anxiety, inability to complete monitoring, changing life circumstances or a change in how the patient values treatment risks can reasonably change the management decision after discussion with the clinical team.
Do not convert a surveillance patient to treatment from one abnormal PSA value alone. A change in PSA or MRI should be interpreted as new information that may require confirmation. The management decision should be based on the updated total risk picture, with biopsy progression carrying particular weight.
05What Are the Long-Term Outcomes and Trade-Offs of Active Surveillance?
Long-term prostate-cancer mortality can remain low in appropriately selected localized disease
Randomized evidence supports the idea that many men with screen-detected localized prostate cancer have time to make a measured treatment decision.
In the ProtecT trial, 1,643 men with localized prostate cancer were randomly assigned to active monitoring, prostatectomy or radiotherapy and followed for a median of 15 years.
Prostate cancer-specific mortality was low in all three groups:
- active monitoring: 3.1%;
- prostatectomy: 2.2%;
- radiotherapy: 2.9%.
The differences in prostate cancer-specific mortality were not statistically significant.
Did monitoring have the same progression risk as immediate treatment?
No.
At 15 years, metastatic disease occurred in:
- 9.4% of the active-monitoring group;
- 4.7% of the prostatectomy group;
- 5.0% of the radiotherapy group.
Clinical progression was also more common with active monitoring.
Can the ProtecT monitoring arm be treated as modern active surveillance?
Not exactly.
ProtecT began enrollment before contemporary multiparametric MRI, MRI-targeted biopsy and current surveillance protocols became routine.
Its active-monitoring arm relied more heavily on PSA than modern surveillance programs do.
The trial is therefore highly informative about the long natural history of localized prostate cancer and the trade-off between immediate treatment and monitoring, but its monitoring protocol should not be assumed to be identical to current MRI-integrated active surveillance.
ProtecT illustrates the central surveillance trade-off: 15-year prostate-cancer mortality remained low regardless of assigned strategy, but metastases and clinical progression were more frequent with active monitoring than with immediate prostatectomy or radiotherapy. Modern active surveillance attempts to reduce that risk through better upfront MRI/biopsy classification and structured repeat assessment.
What is the main benefit of active surveillance?
The principal benefit is avoiding or postponing adverse effects from treatment that may not yet be necessary.
This can preserve:
- urinary continence;
- erectile and sexual function;
- bowel function;
- and freedom from surgical or radiation-related recovery.
What is the main oncological limitation?
The limitation is that a small proportion of cancers can be under-sampled initially or progress while the patient is being monitored.
That is why high-quality entry assessment and reliable follow-up are essential.
Can active surveillance cause anxiety?
Yes.
Some patients find the idea of living with untreated cancer psychologically difficult.
EAU guidance notes that anxiety occurs in a minority of surveillance patients and can be a valid reason to reconsider management, while psychological support may help patients who otherwise remain suitable for surveillance.
When does active surveillance become watchful waiting?
The distinction is based on treatment intent.
A person can remain on surveillance while curative treatment remains meaningful if reclassification occurs. As age or comorbidity increases and life expectancy shortens, the management strategy may transition toward watchful waiting, where treatment is primarily introduced for symptoms or clinically important progression rather than with the intention of cure.
The dedicated comparison is explained in Active Surveillance vs Watchful Waiting.
| Feature | Active surveillance | Watchful waiting |
|---|---|---|
| Treatment intent | Preserve the option of curative treatment if meaningful progression occurs. | Usually symptom control and quality of life rather than delayed curative treatment. |
| Typical patient | Favorable localized cancer with enough life expectancy to benefit from later cure. | Often limited life expectancy, major comorbidity or a situation where curative treatment is unlikely to add meaningful benefit. |
| Monitoring intensity | Structured PSA, clinical review, MRI and repeat biopsy according to protocol. | Usually less intensive and focused on clinically important progression or symptoms. |
| Reason to intervene | Biological reclassification while cure is still appropriate. | Symptoms, local complications or disease-related problems requiring palliation. |
Does active surveillance continue forever?
Not necessarily.
Three broad transitions are possible:
- continued surveillance because the cancer remains favorable;
- definitive treatment because the cancer has been reclassified or the patient chooses treatment;
- transition to watchful waiting because age, health or life expectancy changes the treatment goal.
What happens after surgery or radiation if treatment becomes necessary?
Long-term care shifts from surveillance of untreated localized cancer to survivorship and recurrence monitoring after definitive treatment.
That pathway is covered in Prostate Cancer Survivorship.
→How to Interpret a Change During Active Surveillance
| New finding | What it may mean | Typical next step | Does it automatically mean treatment? |
|---|---|---|---|
| One higher PSA result | Biological change, benign fluctuation, inflammation, retention or measurement variation. | Repeat PSA and assess context. | No. |
| Repeated PSA rise / short PSA doubling time | Greater concern for progression. | MRI and repeat biopsy; EAU uses PSA-DT <3 years as a trigger for reassessment. | No. Confirm the cancer state. |
| MRI lesion progression | Possible increase in clinically significant disease. | Targeted/perilesional repeat biopsy as appropriate. | No. Histological confirmation is important. |
| Stable MRI + stable low PSA density | Lower probability of near-term reclassification. | Continue surveillance; selected protocols may individualize repeat-biopsy frequency. | No. |
| Upgrade to Grade Group 3 or higher | Cancer has moved outside standard favorable-surveillance biology. | Re-stage risk and discuss definitive treatment. | Usually a strong treatment discussion trigger. |
| Cribriform / intraductal carcinoma | Adverse histological architecture. | Reassess suitability for surveillance and discuss treatment. | Strong reason to leave standard EAU surveillance criteria. |
| Patient no longer wants surveillance | Preference or psychological burden has changed. | Shared decision-making about surgery, radiation or continued surveillance with support. | Not biologically required, but patient preference matters. |
Key Points
- Active surveillance is a structured management strategy for favorable localized prostate cancer.
- Low-risk prostate cancer is the core surveillance population.
- Selected favorable intermediate-risk, low-volume Grade Group 2 cancers can also be considered.
- Grade Group 3 and higher disease are generally outside standard surveillance protocols.
- Cribriform and intraductal carcinoma are important adverse pathological findings.
- PSA is monitored serially, but one PSA increase should not automatically trigger treatment.
- Current EAU surveillance guidance uses PSA at least every six months.
- A PSA doubling time under three years is a reason for MRI and repeat biopsy in the EAU framework.
- MRI helps identify change and target repeat biopsy but should not be treated as a standalone definitive-treatment trigger.
- Repeat biopsy remains central because pathological upgrading or adverse architecture can confirm reclassification.
- EAU guidance generally incorporates repeat biopsy every two to three years, although schedules are individualized.
- ProtecT showed very low 15-year prostate-cancer mortality across monitoring, surgery and radiotherapy, but metastases and progression were more common with monitoring.
- ProtecT used a less intensive active-monitoring protocol than contemporary MRI-integrated active surveillance.
- Active surveillance and watchful waiting differ primarily in treatment intent.
- Moving from surveillance to surgery or radiation after confirmed progression is part of the strategy, not evidence that surveillance “failed.”
Clinical bottom line: active surveillance is safest when favorable prostate cancer is accurately characterized at entry and monitored with a reliable protocol. Low-risk disease is the core group, while selected favorable intermediate-risk Grade Group 2 cancers may also qualify. PSA and MRI are valuable early-warning tools, but neither should automatically force treatment. Their role is to identify when the disease needs closer reassessment. Repeat pathology remains central because a meaningful change in Grade Group, adverse architecture or tumor extent can confirm that the cancer has moved outside the surveillance window. The purpose is not to avoid treatment at any cost; it is to avoid unnecessary treatment while preserving timely curative treatment when the cancer genuinely changes.
Medical disclaimer: This article provides general medical education about active surveillance for prostate cancer. Eligibility and follow-up schedules vary between guidelines, institutions and individual patients. A surveillance plan should be based on pathology, Grade Group, amount of Gleason pattern 4, PSA and PSA density, MRI, biopsy volume, adverse histology, health, life expectancy, family/genetic context where relevant and the patient’s ability and willingness to complete follow-up with the treating clinical team.
For the broader management pathway, return to Prostate Cancer Treatment. For the disease framework, return to the Prostate Cancer hub. The next guide distinguishes Active Surveillance vs Watchful Waiting. After definitive local treatment, long-term follow-up moves into Prostate Cancer Survivorship.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: active-surveillance eligibility, low- and favorable intermediate-risk selection, monitoring, MRI, repeat biopsy and criteria for changing management.
- European Association of Urology — Follow-up: definitions and clinical distinction between active surveillance and watchful waiting.
- American Urological Association / ASTRO — Clinically Localized Prostate Cancer Guideline: principles of active surveillance, PSA reassessment, MRI and repeat biopsy.
- National Cancer Institute — Prostate Cancer Treatment PDQ: patient-facing definitions of active surveillance, watchful waiting and treatment pathways.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Health Professional Version: monitoring components, conservative-management evidence and treatment context.
- Hamdy et al., New England Journal of Medicine — Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer: long-term mortality, metastasis and progression results from the ProtecT randomized trial.
